+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome



Proton pump inhibitors in patients treated with aspirin and clopidogrel after acute coronary syndrome



Revista Portuguesa de Cardiologia 29(10): 1511-1520



Clopidogrel is an antiplatelet agent converted to its active metabolite by cytochrome P-450 isoenzymes. Numerous drugs are known to inhibit P-450 isoenzymes, including proton pump inhibitors (PPIs), which are often associated with aspirin and clopidogrel to prevent adverse gastrointestinal effects. In vitro studies first showed that PPIs reduced the antiplatelet effect of clopidogrel, while recent clinical studies have raised concerns that the addition of a PPI to clopidogrel in acute coronary syndrome (ACS) patients could actually increase the risk of recurrent cardiovascular events. The aim of this study was to evaluate whether the prescription of a PPI conferred a worse prognosis in patients discharged with aspirin and clopidogrel treatment after ACS. A total of 876 patients admitted with ACS and discharged with aspirin and clopidogrel, with a planned duration of at least six months, from January 2004 to March 2008, were reviewed. Patients were classified in two groups according to whether or not a PPI was prescribed at discharge. The PPIs considered were those mainly metabolized by cytochrome P-450 2C19. We excluded patients with insufficient information available on either prescription or clinical records that could allow clearly confirm or exclude exposure to a PPI. Primary end points were six-month all-cause mortality and the composite of death, myocardial infarction and unstable angina at six months. Of the 802 patients considered for further analysis, 274 (34.2%) individuals were medicated with a PPI in addition to dual antiplatelet therapy. Patients taking PPIs were older, more often had renal insufficiency and less often had a history of coronary revascularization and smoking. They more often presented with Killip class >I and lower hemoglobin concentration on admission. There were no significant differences between the two groups in terms of medical treatment (during hospital stay and at discharge) or invasive procedures. By multivariate analysis, independent and positive predictors of PPI prescription were older age and lower hemoglobin concentration on admission. Patients taking PPIs had a slightly higher prevalence of six-month mortality (6.5% vs. 3.9%) and of the composite end point (12.9% vs. 9.2%), although without statistical significance. By multivariate analysis including potential confounding variables, the prescription of a PPI on top of aspirin and clopidogrel was still n ot associated with a worse prognosis. In the present study, PPI precription in addition to aspirin and clopidogrel after ACS was not associated with a worse six-month prognosis.

(PDF emailed within 1 workday: $29.90)

Accession: 055260373

Download citation: RISBibTeXText

PMID: 21265493


Related references

The prophylactic use of a proton pump inhibitor (PPI) in patients treated with clopidogrel and aspirin for an acute coronary syndrome or placement of a coronary stent reduces the rate of upper gastrointestinal bleeding with no apparent increase in cardiovascular events. Internal and Emergency Medicine 6(2): 159-160, 2011

One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study. Journal of Cardiovascular Medicine 13(12): 783-789, 2013

Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome. Circulation 120(23): 2322-2329, 2010

Cardiovascular and gastrointestinal events of three antiplatelet therapies: clopidogrel, clopidogrel plus proton-pump inhibitors, and aspirin plus proton-pump inhibitors in patients with previous gastrointestinal bleeding. Journal of Gastroenterology 46(1): 39-45, 2011

Cardiovascular Outcomes Associated with Concomitant Use of Clopidogrel and Proton Pump Inhibitors in Patients of Acute Coronary Syndrome in Taiwan. 2012

Cardiovascular outcomes associated with concomitant use of clopidogrel and proton pump inhibitors in patients with acute coronary syndrome in Taiwan. British Journal of Clinical Pharmacology 74(5): 824-834, 2013

Impact of concomitant use of proton pump inhibitors and clopidogrel or ticagrelor on clinical outcomes in patients with acute coronary syndrome. Journal of Geriatric Cardiology 13(3): 209-217, 2016

Letter by Potter and Le Lorier regarding article, "Cardiovascular outcomes and mortality in patients using clopidogrel with proton pump inhibitors after percutaneous coronary intervention or acute coronary syndrome". Circulation 122(5): E414; Author Reply E415-E414; Author Reply E415, 2010

Impact of different proton pump inhibitors on the antiplatelet activity of clopidogrel in combination with aspirin for patients undergoing coronary stent implantation. Zhongguo Ying Yong Sheng Li Xue Za Zhi 26(3): 266-269, 2012

Influence of proton pump inhibitors on clinical outcomes in coronary heart disease patients receiving aspirin and clopidogrel: A meta-analysis. Medicine 97(3): E9638-E9638, 2018

Risk of adverse outcomes associated with concomitant use of clopidogrel and proton pump inhibitors following acute coronary syndrome. JAMA 301(9): 937-944, 2009

Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting. 2012

PWE-188 Do proton pump inhibitors prevent upper gastrointestinal bleeding in patients treated for acute coronary syndrome?. Gut 64(Suppl 1): A294.2-A295, 2015

Effect of individual proton pump inhibitors on cardiovascular events in patients treated with clopidogrel following coronary stenting: results from the Ibaraki Cardiac Assessment Study Registry. Catheterization and Cardiovascular Interventions 80(4): 556-563, 2013

Lack of association between proton pump inhibitors and adverse events in patients taking clopidogrel and aspirin. Evidence-Based Medicine 18(3): E30-E30, 2012